Peptides for Therapy and Diagnosis of Alzheimer's Disease

Author(s): Susanne Aileen Funke, Dieter Willbold.

Journal Name:Current Pharmaceutical Design

Volume 18 , Issue 6 , 2012

Abstract:

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with devastating effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are available. Additionally, AD can be diagnosed with certainty only post mortem, whereas the diagnosis “probable AD” can be established earliest when severe clinical symptoms appear. Specific neuropathological changes like neurofibrillary tangles and amyloid plaques define AD. Amyloid plaques are mainly composed of the amyloid-βpeptide (Aβ). Several lines of evidence suggest that the progressive concentration and subsequent aggregation and accumulation of Aβplay a fundamental role in the disease progress. Therefore, substances which bind to Aβ and influence aggregation thereof are of great interest. An enormous number of organic substances for therapeutic purposes are described. This review focuses on peptides developed for diagnosis and therapy of AD and discusses the pre- and disadvantages of peptide drugs.

Keywords: Alzheimer's disease, , amyloid-β, therapy, peptides, diagnosis, neurodegenerative, symptomatic, dementia, protofibrils, diffusible ligands

Rights & PermissionsPrintExport

Article Details

VOLUME: 18
ISSUE: 6
Year: 2012
Page: [755 - 767]
Pages: 13
DOI: 10.2174/138161212799277752